- Trials with a EudraCT protocol (3,634)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (440)
3,634 result(s) found for: oncology.
Displaying page 6 of 182.
| EudraCT Number: 2012-003981-42 | Sponsor Protocol Number: 2012.2708 | Start Date*: 2014-10-20 |
| Sponsor Name:University Medical Center Groningen [...] | ||
| Full Title: Estrogen receptor and androgen receptor imaging in metastatic breast cancer patients | ||
| Medical condition: Estrogen receptor positive metastatic breast cancer patients | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2016-001335-12 | Sponsor Protocol Number: D5160C00030 | Start Date*: 2016-05-12 |
| Sponsor Name:Hellenic Oncology Research Group | ||
| Full Title: A longitudinal study evaluating molecular changes associated with resistance to first and third (AZD9291) generation EGFR TKIs in patients with EGFR mutant NSCLC using "liquid biopsy" | ||
| Medical condition: Patients with NSCLC | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: GR (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2010-019815-40 | Sponsor Protocol Number: ML25359 | Start Date*: 2011-03-24 | |||||||||||
| Sponsor Name:Skåne University Hospital, Department of Oncology | |||||||||||||
| Full Title: Avastin and chemotherapy followed by a KRAS stratified randomization to maintenance treatment for first line treatment of metastatic colorectal cancer | |||||||||||||
| Medical condition: Patients with previously untreated metastatic colorectal carcinoma. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-000857-11 | Sponsor Protocol Number: 345-449 | Start Date*: 2016-05-27 |
| Sponsor Name:Bank of Cyprus Oncology Centre | ||
| Full Title: A Phase II study of Switch Maintenance Pembrolizumab in patients with Non Small Cell Lung Cancer (NSCLC) who do not progress after First Line Platinum Doublet Chemotherapy | ||
| Medical condition: Non small cell lung cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: CY (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2016-002612-40 | Sponsor Protocol Number: TET-SEL | Start Date*: 2016-10-20 | ||||||||||||||||||||||||||
| Sponsor Name:Department of Oncology Rigshospitalet | ||||||||||||||||||||||||||||
| Full Title: A phase II study of selinexor (KPT-330) in patients with advanced thymic epithelial tumour (TET) progressing after primary chemotherapy. | ||||||||||||||||||||||||||||
| Medical condition: advanced thymic epithelial tumour (TET) progressing after primary chemotherapy | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: DK (Prematurely Ended) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2020-002079-36 | Sponsor Protocol Number: 73750 | Start Date*: 2020-10-20 |
| Sponsor Name:Amsterdam University Medical Centers | ||
| Full Title: TGF-β And PDL-1 inhibition with Bintrafusp alfa in Esophageal Squamous Cell carcinoma combined with chemoradiation TheRapY (TAPESTRY) | ||
| Medical condition: Esophageal squamous cell carcinoma | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-002966-37 | Sponsor Protocol Number: 1-2018BSMO | Start Date*: 2019-01-23 |
| Sponsor Name:Belgian Society of Medical Oncology | ||
| Full Title: Efficacy of Olaparib in advanced cancers occurring in patients with germline mutations or somatic tumor mutations in homologous recombination genes. | ||
| Medical condition: Advanced cancer patients that have a germline mutation or a somatic mutation in their tumor. Prostate and ovarian cancer patients and breast cancer patients who carry a BRCA1/2 mutation will be exc... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2017-003925-13 | Sponsor Protocol Number: CA209-9UP | Start Date*: 2018-02-19 |
| Sponsor Name:Rigshospitalet | ||
| Full Title: A phase II Open Label, two-armed Translational Study of Nivolumab in Combination with Bevacizumab for Recurrent Glioblastoma | ||
| Medical condition: Glioblastoma, recurrent/progressive | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DK (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2013-003946-17 | Sponsor Protocol Number: FIL_PTCL_BV | Start Date*: 2015-09-15 |
| Sponsor Name:Fondazione Italiana Linfomi ONLUS | ||
| Full Title: Phase II study on the role of brentuximab vedotin as single agent in the treatment of relapsed/refractory CD30 positive peripheral T cell lymphoma (PTCL) patients | ||
| Medical condition: RELAPSED/REFRACTORY CD30 POSITIVE PERIPHERAL T CELL LYMPHOMA (PTCL) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: IT (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-000300-38 | Sponsor Protocol Number: 001610 | Start Date*: 2021-02-05 |
| Sponsor Name:Antwerp University Hospital | ||
| Full Title: Vaccination against cOvid-19 In CancER patients under active treatment (Belgium, B-VOICE) | ||
| Medical condition: Onco-hematological patients | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-003048-22 | Sponsor Protocol Number: Uni-Koeln-3571 | Start Date*: 2020-06-16 | |||||||||||
| Sponsor Name:Universität zu Köln | |||||||||||||
| Full Title: A phase II trial to evaluate safety and efficacy of adding durvalumab (MEDI4736) to standard neoadjuvant radiochemotherapy and of adjuvant durvalumab +/- tremelimumab in locally advanced esophageal... | |||||||||||||
| Medical condition: locally advanced esophageal adenocarcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-003857-27 | Sponsor Protocol Number: LUPSA | Start Date*: 2020-01-23 |
| Sponsor Name:Radboudumc | ||
| Full Title: 177Lu-PSMA Radioligand Therapy for advanced salivary gland cancer, a phase II pilot study. | ||
| Medical condition: Salivary gland cancer. More specifically two subtypes: adenoid cystic carcinoma and salivary duct carcinoma. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2012-004113-13 | Sponsor Protocol Number: CLDE225XBE01T | Start Date*: 2012-11-05 |
| Sponsor Name:GZA vzw, GZA Ziekenhuizen, Sint-Augustinus | ||
| Full Title: A Phase II, Open-Label, Safety, Efficacy and Pharmacodynamic Study of oral sonidegib in patients with Basal Cell Carcinoma (BCC) and prior exposure to Hedgehog Pathway inhibitors | ||
| Medical condition: Basal Cell Carcinoma | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2004-003906-81 | Sponsor Protocol Number: A7-2 | Start Date*: 2005-01-14 |
| Sponsor Name:Oncology Institute of Vilnius University | ||
| Full Title: Chemoradiation with once weekly gemcitabine for invasive bladder cancer | ||
| Medical condition: Invasive transitional cell bladder cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: LT (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2005-003867-21 | Sponsor Protocol Number: | Start Date*: 2005-12-21 |
| Sponsor Name:Sahlgrenska University Hospital | ||
| Full Title: Induction chemotherapy with docetaxel and cisplatin followed by radiotherapy concomitant with cetuximab for locally advanced stage III non-small cell lung cancer- amulticentre, open label non-rando... | ||
| Medical condition: Patient with locally advanced stage III non-small cell lung cancer. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2004-004243-21 | Sponsor Protocol Number: M200-1205 | Start Date*: 2005-03-15 |
| Sponsor Name:PDL BioPharma, Inc. | ||
| Full Title: Phase 2 Open-Label Study of Volociximab (M200) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Cancer Not Previously Treated with Chemotherapy | ||
| Medical condition: metastatic pancreatic cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2007-001783-75 | Sponsor Protocol Number: SATCG-4 | Start Date*: 2008-03-31 |
| Sponsor Name:Department of Oncology, Lund University Hospital | ||
| Full Title: Phase 2 trial with Avastin and Doxorubicin postoperatively for patients with anaplastic thyroid carcinoma | ||
| Medical condition: Patients that suffer from anaplastic thyroid cancer and have completed our "standard" initial therapy with radiotherapy and chemotherapy, and has been macroscopical radically resected after complet... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-001794-77 | Sponsor Protocol Number: SilCOVID19 | Start Date*: 2020-06-10 |
| Sponsor Name:INSTITUT CATALÀ D'ONCOLOGIA GIRONA - HOSPITAL JOSEP TRUETA | ||
| Full Title: Phase II Clinical Trial to evaluate the efficacy of silibinin supplementation in the prevention of the progression of the respiratory failure in patients with onco-hematological diseases and infect... | ||
| Medical condition: COVID19 respiratory failure | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2013-004773-27 | Sponsor Protocol Number: AALL08B1 | Start Date*: 2014-03-07 | |||||||||||
| Sponsor Name:Children's Oncology Group | |||||||||||||
| Full Title: Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) | |||||||||||||
| Medical condition: Acute Lymphoblastic Leukemia | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: IE (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-002524-16 | Sponsor Protocol Number: 240562-2013-01 | Start Date*: 2014-01-10 |
| Sponsor Name:Dept of Oncology. Haukeland University Hospital | ||
| Full Title: Everolimus and temozolomide as first-line treatment in advanced gastrointestinal neuroendocrine carcinoma (G3) with a Ki67 of 20-55% | ||
| Medical condition: Everolimus and temozolomide as first-line treatment in advanced gastrointestinal neuroendocrine carcinoma (G3) with a Ki67 of 20-55% | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Completed) DK (Completed) | ||
| Trial results: View results | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
